Effective intracellular delivery for the next generation of medicine
EndoRel Biosciences is focused on furthering the development of intracellular therapeutics. We are commercializing a novel peptide-based technology to provide robust cytosolic delivery for RNA therapeutics and other biomacromolecules.
Facing the Challenge of Delivery
Over 80% of proteins associated with disease cannot be targeted with current therapeutics, so researchers and drug developers are increasingly turning to innovative biomacromolecules to address disease at the RNA level.
Drugs that work on RNA (RNA therapeutics) are a considerable advance but come with their own challenges, significant of which is delivering the drug to the right part of the cell – the cytosol.
Poor cytosolic delivery reduces drug potency, leading to higher costs, lower safety, and prevents promising therapeutics from reaching the clinic. By improving cytosolic delivery, EndoRel’s technology advances the development of safer more effective drugs for patients.